iifl-logo-icon 1

Sharon Bio-Medicine Ltd Share Price

3.3
(-4.35%)
Mar 28, 2019|03:24:26 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Sharon Bio-Medicine Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

3.3

Prev. Close

3.45

Turnover(Lac.)

0.29

Day's High

3.3

Day's Low

3.3

52 Week's High

0

52 Week's Low

0

Book Value

-14.82

Face Value

2

Mkt Cap (₹ Cr.)

39.25

P/E

2.01

EPS

1.6

Divi. Yield

0

Sharon Bio-Medicine Ltd Corporate Action

10 Apr 2024

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

Sharon Bio-Medicine Ltd NEWS AND UPDATE

No Record Found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Sharon Bio-Medicine Ltd SHAREHOLDING SNAPSHOT

11 Oct, 2024|04:59 AM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 0.00%

Foreign: 0.00%

Indian: 0.00%

Non-Promoter- 0.20%

Institutions: 0.19%

Non-Institutions: 99.80%

Custodian: 0.00%

Share Price

Sharon Bio-Medicine Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Y/e 31 Mar( In .Cr)Mar-2016Jun-2015Jun-2014Jun-2013

Equity Capital

37.51

37.51

101.67

65.31

Preference Capital

0

0

0

0

Reserves

-219

80.57

242.27

178.62

Net Worth

-181.49

118.08

343.94

243.93

Minority Interest

View Balance Sheet
Y/e 31 Mar( In .Cr)Mar-2016Jun-2015Jun-2014Jun-2013

Revenue

253.45

833.95

1,313.76

1,059.49

yoy growth (%)

-69.6

-36.52

23.99

34.95

Raw materials

-332.25

-808.49

-1,112.74

-902.07

As % of sales

131.08

96.94

84.69

85.14

Employee costs

-16.54

-19.82

-18.87

-14.31

View Profit & Loss
Y/e 31 Mar( In .Cr)Mar-2016Jun-2015Jun-2014Jun-2013

Profit before tax

-217.88

-144.56

84.75

66.18

Depreciation

-15.01

-19.16

-15.35

-12.12

Tax paid

-9.96

-4.66

-15.13

-13.33

Working capital

-262.07

-118.82

152.7

135.55

Other operating items

View Cash Flow
Y/e 31 MarMar-2016Jun-2015Jun-2014Jun-2013

Growth matrix (%)

Revenue growth

-69.6

-36.52

23.99

34.95

Op profit growth

289.25

-121.89

30.35

26.46

EBIT growth

188.51

-135.51

31.24

25.08

Net profit growth

32.47

-424.43

31.7

27.02

View Ratios
Particulars (Rupees in Crores.)Mar-2016Jun-2015Jun-2014Jun-2013Jun-2012

Gross Sales

253.45

838.46

1,324.79

1,073.52

804.14

Excise Duty

0

0

0

0

0

Net Sales

253.45

838.46

1,324.79

1,073.52

804.14

Other Operating Income

0

0

0

0

0

Other Income

1.95

2.63

1.92

1.19

1.24

Sharon Bio-Medicine Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,901.95

162.714,52,850.48237.820.724,409.7498.75

Divis Laboratories Ltd

DIVISLAB

6,142.25

94.941,57,701.614300.52,063507.93

Cipla Ltd

CIPLA

1,595.75

32.911,30,708.751,055.940.83,752.25346.39

Torrent Pharmaceuticals Ltd

TORNTPHARM

3,497.05

77.551,16,560.454690.812,394201.77

Dr Reddys Laboratories Ltd

DRREDDY

6,599.2

26.661,09,845.921,417.20.615,823.91,458.55

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Sharon Bio-Medicine Ltd

Management

Register Office

Registrar Office

Chairman & Managing Director

Savita Gowda

Whole-time Director

Lalit Misra

Director

Nivedita Patil

Director

Harish Palecanda

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Incorporated in 1989,Sharon Bio-Medicine Ltd is engaged in the pharmaceuticals/chemicals segment.The company had developed a number of products in active pharmaceutical ingredient (API), intermediates and formulations. During the fiscal year ended June 30, 2010, it had set up an active pharmaceutical ingredients plant in Taloja near Navi Mumbai.The company had installed capacity of 150,000 liters of reactors capacity of API and intermediates, and 2.5 billion tablets per shift per annum and one billion capsules per shift per annum. Its products include Trimetazidine Di Hydrochloride, Ketoconzole, Pentaprazole, Amlodipine Besylate, Atomoxetine Hcl, Carisoprodl, Closantel Base, Glimepiride, Ketoconazole, Nifedipibe, Racecadotril, Toldimfos, Telmisartan, Tamsulosin, Itraconazole, Mesalazine, Lansoprazole and Doxorubicin Inj.In January 2010,the Company started its toxicology laboratory and research and development unit at Taloja, Navi Mumbai.
Read More

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS

  • Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020
  • Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.
  • Pay 20% upfront margin of the transaction value to trade in cash market segment.
  • Investors may please refer to the Exchange’s Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.
  • Check your Securities / MF / Bonds in the consolidated account statement issued by NSDL/CDSL every month.
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day.” – Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets – once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor’s account.

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp